

Hamari Chemicals can offer your company...

- **Cost performance, high quality, and environmentally friendly services.**
- **More than 55 years of experience in custom manufacturing.**
- **More than 60 reactions on commercial scale (500 – 5000 L).**
- **cGMP Manufacturing facilities.**
- **Process development, Method validation and Stability testing.**
- **FTE-Full Time Equivalent study.**
- **API Development Service for IND and NDA.**




Timeline of IND Project

Actual Example

IND Project (total steps 5)

GLP-API 2 Lot, GMP-API 1 Lot



Upon Request Hamari Can Provide:

- **Master Plan and Protocol**
- **Weekly Report**
- **Monthly Report**
- **End of Synthesis Process Development Report**
- **End of Campaign Manufacturing Report**
- **Telephone Conferences**






- **Peptides** → Using **SPPS** and Solution phase synthesis.
- **Reduction** → Reductive amination using metal catalysts.
- **Chiral Technology** → Asymmetric transfer Hydrogenation
- **Alkylation** → Negishi and Suzuki reaction
- **Heterocyclics** → Indoles and Quinolines using **Nitration**
- **Oxidation** → Swern, OXONE, TEMPO, RuCl₃ and Sharpless
- **Halogenation** → Chlorination (POCl₃), Bromination (NBS, Br₂)
- **Etherification** → Phase transfer catalyst such as TBAB
- **Glycosylation** → Using trichloroacetimidate as the glycosyl donor
- **Nucleic Acid** → API for antiviral agents



Peptide Manufacturing

◆ **More than 30 years of experience in peptide synthesis.**



Zinc Carnosine / Polaprezinc

- API in Japan
- Dietary supplement in USA

Capacity / kg to ton scale

Capacity	(maximum per year)
di-peptide	: 50 tons
tri-peptide	: 20 tons
tetra-peptide	: 10 tons
penta-peptide	: 10 tons
hexa-peptide	: 5 tons



- ◆ **Expertise in small to medium length molecular peptides.**
- ◆ **Extensive technology using Solution Phase Synthesis.**
- ◆ **Experience in cGMP synthesis for clinical studies.**
- ◆ **NEW-Acquired resources and equipment for Solid Phase Synthesis.**

Manufacturing Experience

Peptide projects

<i>di</i>	<i>-peptide</i>	:	9
<i>tri</i>	<i>-peptide</i>	:	10
<i>tetra</i>	<i>-peptide</i>	:	7
<i>penta</i>	<i>-peptide</i>	:	6
<i>hexa</i>	<i>-peptide</i>	:	1
<i>hepta</i>	<i>-peptide</i>	:	1
<i>Nona</i>	<i>-peptide</i>	:	1
<i>deca</i>	<i>-peptide</i>	:	1
<i>Peptide mimic</i>		:	1
Total projects (2006-2011)			37

Custom Manufacturing

- ◆ **Intermediates for**
 - ACE inhibitors
 - Anti-cancer drugs
 - HIV protease inhibitors
- ◆ **Cosmetic substances**
- ◆ **Dietary supplements**




Peptides - Custom Manufacturing



ACE Inhibitors

Lisinopril Ester/FARGA-3 (Europe)



Manufacturing

- ◆ Commercial (Yonezawa)
- ◆ Capacity : 30 tons / year
- ◆ Purity: >99%, RSS: <0.5%
- ◆ In accordance with cGMP

Di-peptide Derivative (Japan)

Manufacturing

- ◆ Commercial (Yonezawa)
- ◆ Capacity : 1.5 tons / year
- ◆ In accordance with cGMP

Di-peptide Derivative (Japan)

Manufacturing

- ◆ Commercial (Yonezawa)
- ◆ Capacity : 500kg / year
- ◆ In accordance with cGMP



Peptides - Custom Manufacturing



Anti-Cancer Drugs

Commercial : Currently ongoing

- ◆ *Hexa-peptide 150 kg / year (25 kg / Lot) His, Trp, Ser, etc...*
- ◆ *Tri-peptide 30 kg / year (15 kg / Lot) Arg, etc...*

IND Products : 2006-2011


- | | | | |
|------------------------|-------------------|----------------------------|---------------|
| ◆ <i>Tri-peptide</i> | <i>1 Projects</i> | <i>30 kg</i> | <i>(2008)</i> |
| ◆ <i>Tetra-peptide</i> | <i>2 Projects</i> | <i>1kg, 1kg</i> | <i>(2010)</i> |
| ◆ <i>Penta-peptide</i> | <i>4 Projects</i> | <i>10 kg, 15 kg, 10 kg</i> | <i>(2008)</i> |
| ◆ <i>Deca-peptide</i> | <i>1 Project</i> | <i>50 g</i> | <i>(2008)</i> |
| ◆ <i>Hepta-peptide</i> | <i>1 Project</i> | <i>1 kg</i> | <i>(2009)</i> |
| ◆ <i>Peptide mimic</i> | <i>2 Projects</i> | <i>10 kg</i> | <i>(2006)</i> |
| | | <i>2 kg, 8 kg</i> | <i>(2007)</i> |



Peptides - Custom Manufacturing




Intermediates and API for LH-RH analogues




APO(Ac-D-2-Nal-D-4-CIPhe-D-3-Pal)

Registry Number:129225-22-5

HPLC purity : NLT 99%



Peptide-L-Arg(nitro)-Pro-D-Ala-NH2




Peptide-Lys(Ipropyl.X)-Pro-D-Ala-NH2

◆ We are able to provide our process development for intermediates and API of LH-RH analogs such as Degarelix and Abarelix etc...



Reduction Reactions

- *Extensive experience in safely handling Metal catalysts.*



Catalysts & Reagents

- *Our capability to use chemical reagents*

Autoclaves

Osaka

500L Hastelloy	1.0 MPa
500L SUS	0.5 MPa
100L SUS	0.2 Mpa
10L SUS	2.0 Mpa
1000L GL	0.1 Mpa


Yonezawa

2500L SUS	1.0 MPa
1800L SUS	1.0 MPa
1700L SUS	1.0 MPa
1000L SUS	0.2 MPa
500L SUS	6.8 MPa




Reduction Experience


Asymmetric Schiff base reduction (H_2 / Raney Ni , 30 tons / year)



Selective hydrogenation by using Pd-C (without dehalogenation)





Reduction with DIBAH on commercial scale



Hamari Chiral Technology



Asymmetric Transfer Hydrogenation using Chiral Ru- and Ir-catalysts




Chiral Ru-complex	ee(%)
arene-Ru(II)-TsDPEN	ca.20%ee
Hamari catalyst Ru	40%ee
Hamari catalyst Ir	80%ee

Please note !

- **Asymmetric synthesis** Instead of **optical resolution**.
- When it is not appropriate to use other catalysts.

Hamari is able to provide

Full Time Equivalent study needed for your custom synthesis
Using our **Asymmetric Transfer Hydrogenation** technology.



X=Ru , Ir




Hamari Chemicals, Ltd.




Cryogenic reactions

- ◆ ~ -90°C max. 1000L
- ◆ ~ -50°C max. 3000L

Grignard Reaction




Mitsunobu reaction using DIAD



* DIAD : Diisopropyl azodicarboxylate

Olefination -Horner-Emmons and Wittig reactions




Horner-Emmons

Wittig

Base um (*n*-BuLi), LDA, NaH, *tert*-BuOK, *tert*-BuONa, MeONa, Li, etc.

Etherification

PTC-catalyzed (e.g. TBAB)
Mild condition (<80°C)
High yield (>90%)




Carbazole Derivatives

Quinoline & Quinazoline Derivatives



Hamari Chemicals, Ltd.


Negishi Cross Coupling



Manufacturing

- ◆ Pilot plant : Osaka
- ◆ Manufacturing : 50kg / Batch
- ◆ Residual Pd : NMT 1 ppm level
- ◆ In accordance with cGMP

Suzuki-Miyaura Cross Coupling



Manufacturing

- ◆ Commercial : Yonezawa
- ◆ Manufacturing : 100kg / Batch
- ◆ Residual Pd : NMT 1 ppm level
- ◆ In accordance with cGMP

Mizoroki-Heck Reaction




Manufacturing


- ◆ Commercial : Yonezawa
- ◆ Manufacturing : 100kg / Batch
- ◆ Residual Pd : NMT 1 ppm level
- ◆ In accordance with cGMP




Heterocyclic Derivatives




Quinolines




Quinazolines




Isoquinolines




Carbazoles




Thiophenes




Imidazoles



Aminothiazoles



Oxazoles




Indoles




Heterocyclic Derivatives


Leimgruber - Batcho indole synthesis



Quinazolins synthesis




Oxazole synthesis and the following LiAlH₄ - reduction





Oxidation

Safely handling reagents such as CAN, TEMPO, Oxone[®], MnO₂ and Sulfonium salts (Swern oxid.)

CAN : (NH₄)₂Ce(NO₃)₆



TEMPO





Oxone[®] ; Potassium Peroxymonosulfate



Swern and related oxidations










MnO₂ : activated type



Nucleic Acid Derivatives

API and Intermediates for antiviral agents



IND Products : 2007-2010

Anti HIV project ; non-GMP 2Lot(1kg, 15kg), GMP 1Lot 1(3kg)




Types of reactions that Hamari is able to perform through our affiliates


➤ **Fluorination Reactions**




Sulfur Tetrafluoride




Fluorine




Nucleophilic Fluorinations




Electrophilic Fluorinations







(Perfluoroalkyl) Trimethylsilanes



Halogen Exchange





Fluorinating Building Blocks Available



Methods for Introduction of CF_n Groups



CF_n-transfer reagents= CF₂I₂, FSO₂CF₂CO₃Me, PhSO₂CF₂H, PhSO₂CFH₂



Types of reactions that Hamari is unable to perform

- **High temperature reactions (200-300°C)**
- **Precise Distillations for Purification**
- **Phosgene Chemistry**
- **Reductions using Diborane**
- **Oxidations using Ozone**
- **Photo-reactive Chemistry**



Thank you very much for your time and attention
“Your Partner for the Future”



CPhI Worldwide 2011
In Frankfurt , Booth #30H02



Hamari Chemicals, Ltd.
<http://www.hamarichemicals.com>



Hamari Chemicals, Ltd.